Members |
targetComponentId |
Drug cream, 0,1% |
Cream |
Drug cream, 0,25% |
Cream |
Drug cream, 0,5% |
Cream |
Drug cream, 1% |
Cream |
Drug cream, 2,5% |
Cream |
pharmacodépendance |
Substance dependence (disorder) |
Drug dependence - unspecified whether during pregnancy or the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
Drug dependence NOS |
Substance dependence (disorder) |
Drug dependence NOS |
Substance dependence (disorder) |
Drug dependence during childbirth, puerperium (& pregnancy) |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
Drug dependence during pregnancy, childbirth and the puerperium |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
Drug dependence during pregnancy, childbirth or the puerperium NOS |
Substance dependence during pregnancy, childbirth and/or puerperium (disorder) |
Drug dependence in childbirth |
Substance dependence in childbirth |
Drug dependence in mother complicating pregnancy, childbirth AND/OR puerperium |
Substance dependence in mother complicating pregnancy, childbirth and/or puerperium (disorder) |
Drug dependence in remission |
Substance dependence in remission |
Drug dependence, continuous |
Substance dependence, continuous |
Drug dependence, episodic |
Substance dependence, episodic (disorder) |
Drug gel, 0,05% |
Gel |
Drug gel, 0,1% |
Gel |
Drug gel, 0,25% |
Gel |
Drug groups and agents primarily acting on skin adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting autonomic nervous system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting cardiovascular system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting central nervous system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting gastrointestinal system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting musculoskeletal system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting respiratory system adverse reaction |
Adverse reaction to drug |
Drug groups primarily affecting the autonomic nervous system |
Product containing autonomic agent (product) |
Drug induced rash (& ingestion dermatitis) |
Dermatitis caused by substance taken via oral route (disorder) |
Drug level in urine specimen above therapeutic range |
Urine substance level above reference range (finding) |
Drug ointment, 0,025% |
Ointment |
Drug ointment, 0,05% |
Ointment |
Drug ointment, 0,1% |
Ointment |
Drug ointment, 0,2% |
Ointment |
Drug ointment, 0,25% |
Ointment |
Drug ointment, 1% |
Ointment |
Drug ointment, 2,5% |
Ointment |
Drug reaction - CNS drug |
Adverse reaction to drug |
Drug reaction - CNS drug |
Adverse reaction to drug |
Drug reaction - CNS drug NOS |
Adverse reaction to drug |
Drug reaction - CNS drug NOS |
Adverse reaction to drug |
Drug specific allergen extract |
Pharmaceutical / biologic product (product) |
sevrage d'une drogue |
Substance withdrawal |
Drug withdrawal seizure |
Seizure co-occurrent and due to substance withdrawal |
Drug withdrawal syndrome |
Substance withdrawal |
Drug withdrawal syndrome |
Substance withdrawal |
Drug, medicament or biological substance |
Drug or medicament (substance) |
Drug, medicament, or biological substance in urine above reference range |
Urine substance level above reference range (finding) |
impuissance médicamenteuse |
Erectile dysfunction caused by drug |
diabète insipide néphrogénique médicamenteux |
Acquired nephrogenic diabetes insipidus |
trouble causé par un médicament |
Disease |
Drugs in urine abnormal [D] |
Substance in urine detected by screening method (finding) |
médicaments utilisés pour traiter l'hyperuricémie |
Uricosuric agent |
médicaments utilisés dans les troubles métaboliques |
Medicinal product categorised by therapeutic role |
Drusen |
Hyaline body |
Dry battery contents causing toxic effect |
Toxic effect of sulfuric acid |
Duct ectasia |
Dilatation |
Ductal carcinoma in situ - category |
Non-infiltrating intraductal carcinoma |
Dukes-Filatow disease |
Rubeola scarlatinosa |
Dundee cardiovascular risk score |
Dundee Coronary Risk Disk (assessment scale) |
Duodenitis caused by ingestible alcohol |
Duodenitis caused by ethanol (disorder) |
Duodenoscopy: [diagnostic NOS] or [NEC] |
Duodenoscopy |
concept en double |
Duplicate component (foundation metadata concept) |
rapport en double |
Duplicate report (record artifact) |
maladie de Dupuytren traitée par section de l'aponévrose palmaire |
Dupuytren contracture corrected by division of palmar aponeurosis |
Dupuytren's disease of finger(s), nodules with no contracture |
Dupuytren's disease of finger |
Dupuytren's disease of palm, nodules with no contracture |
Dupuytren's disease of palm |
Dyclonine hydrochloride 1% topical solution (product) |
Product containing precisely dyclonine hydrochloride 10 milligram/1 milliliter conventional release cutaneous solution (clinical drug) |
Dynamite, device |
Dynamite stick (physical object) |
Dyphylline + guaifenesin 100mg/100mg elixir |
Product containing precisely diprophylline 6.67 milligram/1 milliliter and guaifenesin 6.67 milligram/1 milliliter conventional release oral solution (clinical drug) |
Dyphylline 160mg/15ml elixir |
Diprophylline 10.7 mg/mL oral solution |
Dyskinesia of esophagus |
Diffuse spasm of esophagus |
Dyssegmental dysplasia with glaucoma syndrome |
Rolland-Debuqois syndrome |
Dyssocial behavior of child or adolescent |
Dyssocial behavior of child or adolescent (finding) |
Dysthyroid ophthalmopathy |
Exophthalmos due to thyroid eye disease (disorder) |
rapport envoyé par courriel |
Email report (record artifact) |
ECG equivocal |
ECG equivocal |
ECG: left ventricular strain |
ECG: left ventricular strain |
Ear flap |
Flap (substance) |
Ear sign or symptom |
Ear and auditory finding (finding) |
Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
Ear/nose/throat symptom NOS |
Ear, nose and throat finding |
Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
Ear/nose/throat symptoms NOS |
Ear, nose and throat finding |
Early onset pauciarticular chronic arthritis |
Juvenile idiopathic arthritis, oligoarthritis (disorder) |
Early operation NOC NOS |
Surgical procedure (procedure) |
Early operation NOC OS |
Surgical procedure (procedure) |
Early operations NOC |
Surgical procedure (procedure) |
Ebola virus |
Genus Ebolavirus (organism) |
Ebola virus Ivory Coast subtype |
Ivory Coast ebolavirus (organism) |
Ebola virus Reston biotype |
Reston ebolavirus (organism) |
Ebola virus Sudan biotype |
Sudan ebolavirus (organism) |
Ebola virus Zaire biotype |
Zaire virus (organism) |
Ebola virus disease |
Ebola virus disease |
Eccrine papillary adenocarcinoma |
Digital papillary adenocarcinoma |
Echinococcus granulosus infection of other site |
Echinococcus granulosus infection |
Echinococcus multilocularis infection of other site |
Echinococcus multilocularis infection |
Echinocyte |
Burr cell |
Echothiophate iodide 0.03% eye drops |
Ecothiopate iodide 300 microgram/mL eye solution |
Echothiophate iodide 0.06% eye drops |
Product containing precisely ecothiopate iodide 600 microgram/1 milliliter conventional release eye solution (clinical drug) |
Echothiophate iodide 0.125% solution |
Ecothiopate (as ecothiopate iodide) 1.25 mg/mL eye solution |